Part­nered with Lil­ly, TVM Cap­i­tal and Tillotts fund oral in­flam­ma­to­ry bow­el dis­ease drug with up to $28M

Mage Bi­o­log­ics de­buted Thurs­day with a $28 mil­lion com­mit­ment from TVM Cap­i­tal Life Sci­ence and spe­cial­ty phar­ma com­pa­ny Tillotts Phar­ma.

The new biotech is cen­tered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER